Treatment with selinexor plus low-dose dexamethasone achieved promising response rates in heavily pretreated refractory multiple myeloma, according to an announcement by Karyopharm Therapeutics.1
For the single-arm, phase 2b STORM trial, researchers enrolled 78 patients with quad-refractory or penta-refractory multiple myeloma. Patients with quad-refractory disease previously received bortezomib, carfilzomib, lenalidomide, and pomalidomide, and their disease was refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and progressed following their most recent treatment.
Those with penta-refractory disease had quad-refractory disease that was also refractory to an anti-CD38 monoclonal antibody, such as daratumumab.
Selinexor in combination with dexamethasone induced an objective response in 20.5% of evaluable patients. The overall response rate was 20.8% and 20.0% for quad-refractory and penta-refractory patients, respectively. Responses included very good partial responses, partial responses, and minor responses.
The safety profile was consistent with previously reported trials, and no new safety signals were observed.
RELATED: Medidata Partnership With MSKCC Harnesses Mobile Technology to Track Quality of Life With Myeloma
Selinexor is also being evaluated in combination with bortezomib and dexamethasone in a broader population of patients with multiple myeloma as part of the pivotal phase 3 BOSTON study.
- Karyopharm reports positive top-line phase 2b STORM results and reviews the planned development path for selinexor in multiple myeloma [press release]. Karyopharm Therapeutics website. http://investors.karyopharm.com/releasedetail.cfm?ReleaseID=987776. Updated September 6, 2016. Accessed September 6, 2016.